Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Forma Therapeutics, a US-based cancer and haematologic disease therapy developer backed by pharmaceutical firms Novartis and Eli Lilly, completed a $319m initial public offering yesterday.
The company went public last Friday, expanding the size of the IPO from 11.8 million to 13.9 million shares and pricing them above the range at $20 each. Its shares closed at $39.95 on Monday and $41.20 last night.
Joint book-running managers Jefferies, SVB Leerink and Credit Suisse have taken up the over-allotment option…
